The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover


Eye on China


Conferences ListingConferences

Pharma Sales

The word that aptly describes this month’s issue in its entirety. Amidst the variety of editorials that came in, we decided to put the spotlight on cancer. The leading cause of death in many a country with few cures and preventive measures in place. Cancer used to be a disease of the developed world but the landscape has changed over the past decade. According to the World Research Fund International, 56% of all cancers occur in less developed nations as compared to 44% in developed countries. The number of cancer victims is expected to increase to 21 million by 2030.

Nanject is being developed in the UK as a novel way of drug delivery akin to the nicotine patch. It is a very promising idea to manage and minimize pain and reduce infection in patients that require regular injections. The researchers hope that the Nanject will improve healthcare in the process.

Our next author is a promising young talent. Here she discusses the plus and minus of synthetic biology. It is becoming a commonplace to create and engineer microbes for medicines. However, creating life raises plenty of ethical questions of which she addresses in this article.

Finally, we have a technological update from pharma titans; Wyatt Technology and Novozymes Biopharma. The rapid advancements in the field has allowed a marked progression in terms of research but these cannot be done without the instruments that accompany the research.

I had the great pleasure of catching up with Thermo Fisher Scientific’s head honcho Cory Stevenson and Greg Herrema during the opening ceremony of the new dry powder media plant in Tuas Biomedical Park to talk about the company’s commitment to Asia and her significance in the life science field.

I would like to take this opportunity to introduce Rachel Lim, who will be taking over the helm for APBN from the October issue onwards. It has been a great pleasure being the Editor for this magazine, the trials and tribulations faced and the eclectic mix of contributors from the research field to the commercial sector that I’ve met, some whom I can call friends. It is with hope that the new successor of APBN will bring the magazine up to the next level, further enriching its content with a fresh set of eyes and editorial wit.

Sulastri Kamis
Asia Pacific Biotech News

Check out our new website at
Sign up for our mailing list to get updates at
Air your views and suggestions by writing to in to the editorial team (Letters to the Editor) at

Click here for the complete issue.